Full Press Release Details
Presentation May 2017 2017 MRI INTERVENTIONS, INC. | 1
herein concerning MRI Interventions, Inc. (the "Company") plans, growth and strategies may include forward-looking
statements within the context of the federal securities laws. Statements regarding the Company's future events, developments
and future performance, as well as management's expectations, beliefs, plans, estimates or projections relating to the future,
are forward-looking statements within the meaning of these laws. Uncertainties and risks may cause the Company's actual
results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks
include those relating to: the Company's ability to obtain additional financing; estimates regarding the sufficiency of
the Company's cash resources; future revenues from sales of the Company's ClearPoint System products; and the Company's
ability to market, commercialize and achieve broader market acceptance for the Company's ClearPoint System products. More
detailed information on these and additional factors that could affect the Company's actual results are described in the
"Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2016, which
has been filed with the Securities and Exchange Commission, and our most recently filed quarterly report on form 10-Q.
2017 MRI INTERVENTIONS, INC. | 2
The Platform Company for MRI-Guided Therapies MRI Interventions: Leader in the Delivery of MRI-Guided Therapies Primary Innovator
in the Field, grown out of the Advanced MR department at Johns Hopkins Extensive Intellectual Property position: 70+ issued US
patents, 45 international Proven track record for conceiving, developing, commercializing and securing clinical adoption for our
MRI-guided therapy platform Rapidly Growing Commercial Business; Established the Industry Platform for MRI-guided, Minimally-Invasive
Neurosurgery Strong and growing clinical footprint: 48 hospitals in the US Accelerating adoption, revenue growth: 8 successive
quarters of record procedures Current procedures include DBS electrode placement, laser ablation, biopsy, drug delivery MRIC's
platform integrates with products from multiple companies (med device companies, imaging companies, biotechs) Expanding Platform
into Adjacent Areas to Address Additional Unmet Medical Needs Expanding platform into the stroke market; Joint Development Agmt
with Mayo Clinic Expanding our capabilities, adding novel ultrasound ablation technology via Co-Dev Agmt with Acoustic MedSystems;
initial market is pancreatic cancer
our existing platform, install base and technologies to enable a rapid, cost-effective path to additional markets 2017
MRI INTERVENTIONS, INC. | 3
MRI-Guided Therapies? Image-guided Therapeutic Procedures Have Become a Mainstay in U.S. Healthcare 1.2 Million Arthroscopic
Procedures 1.5 million Fluoroscopic Procedures 4.0 Million Laparoscopic Procedures MRI Guided Therapeutic Procedures are the Next
Step in this Trend Unique capabilities that no other imaging modality can provide High resolution, three-dimensional, continuous,
no radiation MRI-Guided Procedures are Uniquely Positioned to Address Significant Unmet Medical Needs Functional neurological
diseases (e.g., Parkinson's disease, Epilepsy) Untreatable hemorrhagic stroke (e.g., intracerebral hemorrhage) Certain cancers
(e.g., brain, pancreas) 2017 MRI INTERVENTIONS, INC. | 4
MRI-Guided Therapy Platform is Currently Being Used to: Implant Neuro Stimulation Products from: Medtronic St. Jude Medical
NeuroPace Place Laser Ablation Probes from: Medtronic-Visualase Monteris Medical Deliver Drugs and Biologics from: Voyager Medicenna
Oxford Biomedica International Stem Cell Corporation MRIC Platform Runs on All Major Scanners: Siemens GE Philips IMRIS
2017 MRI INTERVENTIONS, INC. | 5
and Growing User Base of Leading Neurosurgeons ClearPoint Is Installed in 48 Top US Hospitals and Growing
UC San Francisco San Francisco VA Brigham & Women's Stanford Univ Boston Children's UCSF Benioff Childrens
Yale Univ USC Univ of Pitt Med Center UC San Diego Memorial Sloan Kettering Univ of Colo Hackensack Univ Med Center Univ of Utah
Nat. Institutes of Health Univ of Arizona Children's Hosp of Philadelphia Cook Children's Univ of Virginia MD Anderson
Emory University Methodist Hosp Carillion Texas Children's Hosp Duke University Riverside Children's of Alabama Nationwide
Children's CHOA Scottish Rite Children's Mercy Willis Knighton Kansas Univ Med Center Mayo Clinic Jacksonville Univ
of Wisconsin Miami Children's Spectrum Health Ohio State Univ Univ of Michigan Strong Commercial Sales and Clinical
Support Teams in Place 2017 MRI INTERVENTIONS, INC. | 6
of Our Platform: ClearPoint Neuro Navigation System 2017 MRI INTERVENTIONS, INC. | 7
ClearPoint, Minimally Invasive Neuro Procedures Are Performed "Blind"Conventional Stereotactic Procedure ClearPoint
Neuro ProcedureNo real time images images from earlier in the day or week 2017 MRI INTERVENTIONS, INC. | 8
Neuro Navigation System: MRI-Guided NeuroSurgical Platform ClearPoint Components: Capital Sale Recurring Revenue Reusable
Hardware Components Integrated Software Single-Use, Disposable Components Emory University Hospital Univ. of California San Francisco
Univ. of Pittsburgh Medical Center Medical Center 2017 MRI INTERVENTIONS, INC. | 9
on Our ClearPoint Neuronavigation System Platform ClearPoint Procedure Overview: ClearPoint Video ClearPoint Video Entry
and Trajectory Alignment and Insertion 2017 MRI INTERVENTIONS, INC. | 10
Clinical Applications for Our ClearPoint System Platform Electrode Placement and Laser Ablation Drug Delivery Delivering
Therapies to Address Significant Unmet Medical Needs:Parkinson's disease, Epilepsy, Brain Tumor, Dystonia Enabling Multiple
Therapies from Multiple Companies: Electrode Placement: Medtronic, St. Jude, Neuropace Laser Ablation: MDT/Visualase, Monteris
Drug Delivery: Voyager, Medicenna, Oxford Biomedica, Int'l Stem Cell (1) Laser Ablation - MR Thermometry is an MRI-based
functionality available on most MR scanner platforms and it is a feature built into products from several third party vendors.
The ClearPoint system enables MRI-guided procedures and allows physicians to use this inherent MR capability during a procedure.
(2) Drug Delivery - The SmartFlow cannula received 510(k) clearance for injection of cytarabine, a chemotherapy drug, to
the ventricles or removal of CSF from the ventricles during intracranial procedures. Delivery of other therapeutic agents, and
delivery of agents to other areas of the brain, using the SmartFlow cannula is investigational. 2017 MRI INTERVENTIONS,
Business Model for Our Core MRI-Guided Navigation Platform ClearPoint Hardware/Software: $100,000 - $150,000 ASP ClearPoint
Disposables: ~$7,500 ASP per procedure with strong margins Recurring revenue from the sale of disposables Procedures covered by
existing inpatient DRG reimbursement codes Same razor/razorblade model applies to future product sales 2017 MRI INTERVENTIONS,
Neurosurgical Procedure Growth 800 Procedures 650-700 CAGR, 2013 2016: 46% 700 600 500 Q1, 2017: 146
400 Procedures Eight quarters in a 300 row of procedure 200 growth 100 0 2013 2014 2015 2016 2017 Outlook
2017 MRI INTERVENTIONS, INC. | 13
Our Platform: New Procedural Applications 2017 MRI INTERVENTIONS, INC. | 14
MRIC's MRI-Guided Therapy Platform Benefits Larger Patient Populations First, MRIC established the Capability
of the Platform Began with Electrode Placement (DBS) Parkinson's disease, dystonia Expanded to Biopsy Brain Tumor Expanded
to Laser Ablation Probe Placement Epilepsy and Brain Tumor Expanded to Drug Delivery Parkinson's Disease and Brain Tumor
now, Expanding the Reach of the MRI-Guided Platform Expanding Adding Novel Ablation Technology to Platform Initial focus
in Pancreatic Cancer 2017 MRI INTERVENTIONS, INC. | 15
into the Stroke Market Leveraging Existing Capabilities and Install Base Expanding the Reach of the MRIC Platform into
the Stroke Market Joint Development Agreement with Mayo Clinic Dr. Bernard Bendok, Chair of Neurosurgery, Mayo Arizona Large
Stroke Market 5th leading cause of death in US Leading cause of permanent disability
800,000 people in the US every year Initial Stroke Product (ClearAway ) Targets Intracerebral Hemorrhage (ICH) Only major
stroke subtype w/o clearly effective therapy major unmet medical need Affects 80,000 to 100,000 people in the US each year MRIC
market opportunity is 12,000 to 15,000 cases/year 2017 MRI INTERVENTIONS, INC. | 16
MRI-Guided Approach to Intra Cerebral Hemorrhagic Stroke Current Approaches for Hemorrhage Removal and Decompression are Inadequate:
Open craniotomy provides visibility but is highly invasive, destroys brain tissue Minimally Invasive approach has very limited
ability to quantify volume reduction of the hemorrhage or monitor subsequent bleeds Our Unique ClearAway MRI-Guided Therapy
Approach to ICH Detailed, continuous, high resolution, 3 dimensional visibility Minimally invasive approach Expected Path
to Market Builds directly on our ClearPoint Platform ClearPoint software and hardware; SmartFrame Hemorrhage aspiration components
Potential 510(k) regulatory path Projected market introduction as soon as 12-18 months U.S. Market Opportunity = $72 million to
$90 million 95% of Our Existing ClearPoint Adult Sites Have a Stroke Program! 2017 MRI INTERVENTIONS, INC. | 17
our Platform with a Novel Ablation Technology Co-Development Agreement Will Add Additional Capabilities License and Co-Development
Agreement with Acoustic MedSystems (AMS) Leading developer of ultrasound ablation technologies and systems Base technology
has 510k clearance Initial license areas: WW Excl. for Pancreatic Cancer, Excl. Option for Brain Applications AMS Ultrasound
Technology Provides Unique Capabilities Directional Ablation over Other Ablative Energy Sources Precision ablation
over small and large areas Directional and depth control "Protected Zone" between transducer and ablated tissue AMS
Ultrasound Technology Works with MRI Interventions' Technology
components Enhanced by real-time, MRI-guidance Can incorporate real-time MRI-thermometry 2017 MRI INTERVENTIONS, INC. |
Focused First on Pancreatic Cancer Market Pancreatic Cancer Market Major Unmet Medical Need 50,000 patients in US diagnosed
annually 10,000 to 15,000 cases annually are localized, non-metastatic tumors, but untreatable because of the tumor location Our
Therapeutic Approach Targets Untreatable Tumors pancreas Vascular access to get near the tumor Apply ultrasound energy to
ablate the tumor Destroy the tumor Preserve the vessel Expected Path to Market Begin limited sales of existing AMS products
market introduction of integrated pancreatic cancer product as soon as 18 - 24 months Potential 510(k) regulatory path U.S. Market
Opportunity = $50 million to $75 million 2017 MRI INTERVENTIONS, INC. | 19
Pipeline of New Products to Add to our Existing Products Leveraging our MRI-Guided Therapy Platform Projected Development
Pipeline 2017 2018 Q2 Q3 Q4 Q1 Q2 Q3 Q4 New Products in Development ClearPoint Software 2.0 ClearPoint Drug Delivery Cannula